Trial · NCT01214629
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recommended Dose for Phase 2 Studies | LY2523355 | 4.0 | mg/m²/day | ||
| Recommended Dose for Phase 2 Studies | LY2523355 + Pegfilgrastim | 6.0 | mg/m²/day | ||
| Number of Participants With Clinically Significant Effects | 0.125 mg/m²/Day LY | SAEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | 0.25 mg/m²/Day LY | SAEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | 0.5 mg/m²/Day LY | SAEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | 1.0 mg/m²/Day LY | SAEs | 1 | Participants | |
| Number of Participants With Clinically Significant Effects | 2.0 mg/m²/Day LY | SAEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | 4.0 mg/m²/Day LY | SAEs | 5 | Participants | |
| Number of Participants With Clinically Significant Effects | 5.0 mg/m²/Day LY | SAEs | 3 | Participants | |
| Number of Participants With Clinically Significant Effects | 6.0 mg/m²/Day LY | SAEs | 3 | Participants | |
| Number of Participants With Clinically Significant Effects | 4.0 mg/m²/Day LY + 6 mg PEG | SAEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | 6.0 mg/m²/Day LY + 6 mg PEG | SAEs | 11 | Participants | |
| Number of Participants With Clinically Significant Effects | 7.0 mg/m²/Day LY + 6 mg PEG | SAEs | 3 | Participants | |
| Number of Participants With Clinically Significant Effects | 0.125 mg/m²/Day LY | AEs | 1 | Participants | |
| Number of Participants With Clinically Significant Effects | 0.25 mg/m²/Day LY | AEs | 1 | Participants | |
| Number of Participants With Clinically Significant Effects | 0.5 mg/m²/Day LY | AEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | 1.0 mg/m²/Day LY | AEs | 2 | Participants | |
| Number of Participants With Clinically Significant Effects | 2.0 mg/m²/Day LY | AEs | 3 | Participants | |
| Number of Participants With Clinically Significant Effects | 4.0 mg/m²/Day LY | AEs | 13 | Participants | |
| Number of Participants With Clinically Significant Effects | 5.0 mg/m²/Day LY | AEs | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01214629/results